Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration - PubMed (original) (raw)
. 2000 May 4;43(9):1664-9.
doi: 10.1021/jm9909645.
Affiliations
- PMID: 10794683
- DOI: 10.1021/jm9909645
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
L B Knudsen et al. J Med Chem. 2000.
Abstract
A series of very potent derivatives of the 30-amino acid peptide hormone glucagon-like peptide-1 (GLP-1) is described. The compounds were all derivatized with fatty acids in order to protract their action by facilitating binding to serum albumin. GLP-1 had a potency (EC(50)) of 55 pM for the cloned human GLP-1 receptor. Many of the compounds had similar or even higher potencies, despite quite large substituents. All compounds derivatized with fatty acids equal to or longer than 12 carbon atoms were very protracted compared to GLP-1 and thus seem suitable for once daily administration to type 2 diabetic patients. A structure-activity relationship was obtained. GLP-1 could be derivatized with linear fatty acids up to the length of 16 carbon atoms, sometimes longer, almost anywhere in the C-terminal part without considerable loss of potency. Derivatization with two fatty acid substituents led to a considerable loss of potency. A structure-activity relationship on derivatization of specific amino acids generally was obtained. It was found that the longer the fatty acid, the more potency was lost. Simultaneous modification of the N-terminus (in order to obtain better metabolic stability) interfered with fatty acid derivatization and led to loss of potency.
Similar articles
- Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD, Gault VA, Mooney MH, Irwin N, Harriott P, Greer B, Bailey CJ, O'Harte FP, Flatt PR. Green BD, et al. Biol Chem. 2004 Feb;385(2):169-77. doi: 10.1515/BC.2004.035. Biol Chem. 2004. PMID: 15101559 - Therapeutic strategies based on glucagon-like peptide 1.
Deacon CF. Deacon CF. Diabetes. 2004 Sep;53(9):2181-9. doi: 10.2337/diabetes.53.9.2181. Diabetes. 2004. PMID: 15331525 Review. - Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.
Xiao Q, Giguere J, Parisien M, Jeng W, St-Pierre SA, Brubaker PL, Wheeler MB. Xiao Q, et al. Biochemistry. 2001 Mar 6;40(9):2860-9. doi: 10.1021/bi0014498. Biochemistry. 2001. PMID: 11258897 - Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Nauck MA, et al. Am J Physiol. 1997 Nov;273(5):E981-8. doi: 10.1152/ajpendo.1997.273.5.E981. Am J Physiol. 1997. PMID: 9374685 Clinical Trial. - The potential role of glucagon-like peptide 1 in diabetes.
Meier JJ, Nauck MA. Meier JJ, et al. Curr Opin Investig Drugs. 2004 Apr;5(4):402-10. Curr Opin Investig Drugs. 2004. PMID: 15134281 Review.
Cited by
- Effect of C-terminus Conjugation via Different Conjugation Chemistries on In Vivo Activity of Albumin-Conjugated Recombinant GLP-1.
Park J, Bak M, Min K, Kim HW, Cho JH, Tae G, Kwon I. Park J, et al. Pharmaceutics. 2021 Feb 15;13(2):263. doi: 10.3390/pharmaceutics13020263. Pharmaceutics. 2021. PMID: 33672039 Free PMC article. - The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease.
Du H, Meng X, Yao Y, Xu J. Du H, et al. Front Endocrinol (Lausanne). 2022 Nov 17;13:1033479. doi: 10.3389/fendo.2022.1033479. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36465634 Free PMC article. Review. - Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.
Feng P, Yu DM, Chen LM, Chang BC, Ji QD, Li SY, Zhu M, Ding SH, Zhang BZ, Wang SL, Li HT, Lin JN, Wang MJ, Guo JC, Liu J, Liu ZD, Wu ST, Yang JH. Feng P, et al. Acta Pharmacol Sin. 2015 Feb;36(2):200-8. doi: 10.1038/aps.2014.136. Epub 2015 Jan 26. Acta Pharmacol Sin. 2015. PMID: 25619391 Free PMC article. Clinical Trial. - Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.
Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Jacobsen LV, et al. Br J Clin Pharmacol. 2009 Dec;68(6):898-905. doi: 10.1111/j.1365-2125.2009.03536.x. Br J Clin Pharmacol. 2009. PMID: 20002084 Free PMC article. Clinical Trial. - Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide.
Pinkney J, Fox T, Ranganath L. Pinkney J, et al. Ther Clin Risk Manag. 2010 Sep 7;6:401-11. doi: 10.2147/tcrm.s7313. Ther Clin Risk Manag. 2010. PMID: 20856686 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases